Armata Pharmaceuticals, Inc.ARMPNYSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR-63.1%
5Y CAGR-54.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-63.1%/yr
Annual compound
5Y CAGR
-54.6%/yr
Recent deceleration
Percentile
P50
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2024 | 1.94% |
| 2023 | -3.56% |
| 2022 | 74.95% |
| 2021 | 38.57% |
| 2020 | 47.03% |
| 2019 | 100.82% |
| 2018 | 69.80% |
| 2017 | -49.26% |
| 2016 | 42.23% |
| 2015 | -31.23% |